Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: A pilot study

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer accounts for ∼20% of invasive breast cancers and is associated with poor prognostics. The recent outcome of HER2+ breast cancer treatment has been vastly improved owing to the application of antibody-targeted therapies. Trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Xu, Rengen, Yuan, Haiyan, Zhang, Yunning, Cheng, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617483/
https://www.ncbi.nlm.nih.gov/pubmed/31261495
http://dx.doi.org/10.1097/MD.0000000000015872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617483/
https://www.ncbi.nlm.nih.gov/pubmed/31261495
http://dx.doi.org/10.1097/MD.0000000000015872

Ejemplares similares